Optimind Pharma Corp News

Optimind Pharma Provides Corporate Update

TORONTO, ON / ACCESSWIRE / December 19, 2023 / Optimind Pharma Corp. (CSE:OMND) ("Optimind" or the "Company"), an emerging provider of psychedelic therapies, is pleased to announce that Manitari Pharm

AccesswireDec 19, 2023 07:30 ET

Optimind Pharma Corp. Announces Grant of Options

Toronto, Ontario--(Newsfile Corp. - March 10, 2023) - Optimind Pharma Corp. (CSE: OMND) (the "Company") wishes to announce that pursuant to its stock option plan, it has granted stock options to its d

newsfileMar 10, 2023 16:04 ET

Optimind Acquires MindSetting Institute to Integrate Three-Pronged Approach to Its Business and Become Industry Leader in Psychedelic Enhanced Psychotherapy

Optimind looks to accelerate the adoption of the MindSetting(TM) TRIP Protocol for ketamine-assisted therapy and other psychedelic enhanced psychotherapy modalities.Toronto, Ontario--(Newsfile Corp. -

newsfileSep 20, 2022 08:40 ET

Canadian Securities Exchange Reports August 2022 Performance Figures

̶ CSE surpasses 800 listings for the first time ̶Toronto, Ontario--(Newsfile Corp. - September 13, 2022) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced its market stati

newsfileSep 13, 2022 14:35 ET

Optimind Provides Update on Health Canada's Dealer License Under Joint-Venture with Manitari Pharma

Manitari Pharma received approval to begin construction of Security Level 3 safe plus grow rooms, Manitari Pharma is one step closer to obtaining Controlled Substances Dealer's Licence for Psilocybin

newsfileAug 10, 2022 08:40 ET

Optimind Pharma Commences Trading on The CSE Under Ticker Symbol OMND

Toronto, Ontario--(Newsfile Corp. - August 4, 2022) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") today announced its commencement of trading on the CSE (Canadian Securities Exchan

newsfileAug 4, 2022 08:35 ET